Rama Ayash | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Dr. Rama Ayash | Medicine and Health Sciences | Best Researcher Award

Damascus University | Syria

Dr. Rama Ayash is a medical advisor, senior lecturer, and scientific researcher specializing in clinical biochemistry, diabetes research, and molecular mechanisms of β-cell apoptosis. Her primary research focuses on the pathophysiological role of cytokines and death receptors in glucose dysregulation and prediabetes, with particular emphasis on the therapeutic effects of DPP4 inhibitors such as sitagliptin. Her recent publications include groundbreaking studies in Scientific Reports, BMC Endocrine Disorders, and the European Journal of Pharmacology, exploring inflammatory cytokine modulation, apoptotic biomarkers (FAS, TNFR1, TRAIL-R2), and their relationship to β-cell dysfunction. Dr. Rama Ayash’s research contributions advance understanding of early diabetic mechanisms, aiding in the development of targeted therapeutic strategies to preserve pancreatic function. She has also supervised diverse clinical and molecular research projects in cardiovascular pharmacology, endocrine biomarkers, and celiac disease diagnostics, demonstrating her interdisciplinary expertise. Her work integrates clinical biochemistry, molecular diagnostics, and translational medicine, contributing to the growing field of preventive and precision diabetology. Dr. Rama Ayash has been an active conference speaker and scientific presenter, sharing insights on cardio-renal pharmacology, metabolic pathways, and biomarker discovery. Her continuing research endeavors aim to bridge laboratory findings with clinical outcomes to enhance diagnostic accuracy and therapeutic efficacy in metabolic diseases.

Profiles: Google Scholar | ORCID

Featured Publications

• Ayash, R., Kabalan, Y., & Chamaa, S. (2025). Exploring the predictive potentials of IL-1β and TNFR1 in atherogenic risk in prediabetes. Scientific Reports, 15(1), 37369. https://doi.org/10.1038/s41598-025-37369

• Ayash, R., Kabalan, Y., & Chamaa, S. (2025). Association of soluble apoptotic biomarkers (FAS, TNFR1 and TRAIL-R2) with β-cell dysfunction in early glucose dysregulation. BMC Endocrine Disorders, 25(1), 218. https://doi.org/10.1186/s12902-025-0218

• Ayash, R., Kabalan, Y., & Chamaa, S. (2025). Sitagliptin reduces cytokine-induced β-cell apoptosis in prediabetes: A six-month interventional study. European Journal of Pharmacology, 177708. https://doi.org/10.1016/j.ejphar.2025.177708

Chunmei Qin | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Dr. Chunmei Qin | Medicine and Health Sciences | Best Researcher Award

Luzhou People’s Hospital | China

Dr. Chunmei Qin is a highly respected nephrologist and Director at Luzhou People’s Hospital. With over a decade of dedicated experience in clinical practice, research, and academic mentoring, she has played a pivotal role in advancing nephrology care in China. Her scientific acumen and leadership have led her to spearhead more than ten provincial and municipal research initiatives, gaining national recognition for her innovative contributions. As a recipient of multiple prestigious honors, she exemplifies clinical excellence blended with research-driven impact.

Author Profile👤

Scopus

Strengths for the Awards✨

Dr. Chunmei Qin brings over a decade of comprehensive clinical, academic, and research experience in nephrology, making her a competitive candidate for the Best Researcher Award. She has led or participated in 10+ provincial and municipal-level research projects, including those funded by the Luzhou Medical Association, Sichuan Province Medical Research Project Plan, and Luzhou Science and Technology Program. Notably, one of her research outcomes has been recognized as nationally advanced.

She has authored five peer-reviewed articles in respected SCI-indexed journals, with research that spans from kidney failure in diabetic nephropathy patients to oxidative stress mechanisms in diabetic kidney disease. These works contribute meaningfully to both clinical practice and academic discourse. Additionally, she has received multiple accolades, including:

  • Outstanding Young Paper Award by the Sichuan Medical Association.

  • Outstanding Contribution Award by the Municipal Health Commission.

Her active engagement in professional organizations and committees (such as the Nephropathy Branch of the Sichuan Medical Promotion Association) further reinforces her leadership in the field.

🎓 Education

Dr. Qin holds a strong academic foundation in nephrology, built through extensive medical training and continuous professional development. Her academic journey is characterized by a focus on integrating clinical insights with evidence-based research, equipping her with the analytical skills and expertise required to navigate complex patient cases and contribute to impactful studies.

🏥 Experience

Currently serving as Director at Luzhou People’s Hospital, Dr. Qin has amassed significant experience across clinical care, research, and medical education. Her responsibilities encompass managing nephrology units, mentoring junior physicians, and leading interdisciplinary teams in patient-centered care. Her experience extends beyond the bedside to include policymaking contributions at the municipal level through health commissions.

🔬 Research Interests On Medicine and Health Sciences

Dr. Qin’s research interests lie primarily in nephrology, with a special focus on diabetic kidney disease, chronic kidney failure, oxidative stress mechanisms, and the psychological implications of kidney disease. She is passionate about exploring the intersection between metabolic disorders and renal complications, as well as applying molecular approaches to improve patient outcomes.

🏆 Awards

Dr. Qin has received multiple accolades in recognition of her outstanding contributions. These include the Outstanding Young Paper Award from the Sichuan Medical Association and the Outstanding Contribution Award from the Municipal Health Commission. Her work, acknowledged both locally and nationally, reflects her commitment to excellence in nephrology research and healthcare delivery.

📄 Publications

Dr. Qin has authored several impactful studies in internationally recognized SCI journals, demonstrating both breadth and depth in her research:

  1. Qin, C., Wu, Y., Zou, Y., et al. Associations between depressive and anxiety symptoms and incident kidney failure in patients with diabetic nephropathy, BMC Nephrology, 2025; 26:54. Cited by multiple nephrology scholars for its clinical relevance.

  2. Qin, C., Wang, Y., Zhao, L., et al. Clinical and pathological features of Chinese patients with type 2 diabetes, biopsy-proven diabetic kidney disease, and rapid eGFR decline, Diabetes Metab Syndr Obes, 2022; 15:2847–2856. Widely cited for advancing understanding of kidney function trajectories.

  3. Qin, C., Yin, D., Liu, F., et al. Thrombotic thrombocytopenic purpura in a patient on long-term alpha-interferon therapy: a case report, BMC Nephrology, 2023; 24(1):143. Referenced in case studies on rare renal pathologies.

  4. Zhang, R., Qin, C., Zhang, J., et al. DNA hypomethylation of Syk induces oxidative stress and apoptosis via the PKCβ/P66shc pathway in diabetic kidney disease, FASEB Journal, 2024; 38(6):e23564. Significantly cited in molecular nephrology and oxidative stress research.

  5. Qin, C., Li, G., Yuan, Y., et al. Association between uric acid to HDL-C ratio and diabetic kidney disease in US adults, Scientific Reports, 2025; 15:24353. Cited for its epidemiological insights on metabolic markers.

Zhanbo Qu | Medicine | Best Researcher Award

Published on by Forensic Scientist

Dr. Zhanbo Qu | Medicine | Best Researcher Award

Huzhou central hospital | China

Dr. Qu Zhanbo is a dedicated medical professional at Huzhou Central Hospital, with a focus on microbiology, oncology, and gastroenterology. As a researcher, Dr. Qu has made significant contributions to the scientific community, publishing multiple papers in esteemed journals. His academic journey is marked by exceptional achievements, including being recognized as a top graduate innovative talent during his master’s studies.

Professional profile👤

ORCID

Strengths for the Awards✨

  • Research Productivity: Qu Zhanbo has published 2 SCI papers as the first author, 3 SCI papers as a total of first author, and contributed to 16 SCI papers overall. This demonstrates consistent research output and collaboration.

  • Interdisciplinary Focus: His research spans microbiology, oncology, and gastroenterology — fields with significant impact on healthcare, especially in understanding colorectal cancer risk.

  • Recognition and Innovation: Awarded as a top graduate Innovative Talent during his master’s studies, reflecting early recognition for his research potential.

  • Patent Development: Involved in the development of dissolving microneedles of Clostridium butyricum and oxaliplatin, indicating a focus on translational research and innovation.

  • Diverse Publications: Contributions to reputable journals like Aging and Disease, Aging-US, Digestion, and Microbial Biotechnology highlight his research’s acceptance in well-regarded scientific communities.

Education 🎓

Dr. Qu Zhanbo pursued his medical education with a deep interest in understanding complex diseases and their microbial interactions. His academic path laid the foundation for his subsequent research endeavors, where he explored the intersection of microbiology and oncology.

Experience 💼

Currently serving at Huzhou Central Hospital, Dr. Qu combines clinical practice with groundbreaking research. His work spans various domains, including the association of Peptostreptococcus stomatis with colorectal cancer risk. Over the years, he has authored multiple SCI papers and contributed extensively to scientific literature, showcasing his expertise and commitment to advancing medical knowledge.

Research Interests On Medicine🔬

Dr. Qu’s research interests lie at the crossroads of microbiology, oncology, and gastroenterology. His investigations delve into microbial influences on cancer development, aiming to uncover novel insights that could lead to improved diagnostic and therapeutic strategies.

Awards 🏆

Dr. Qu’s academic and research excellence have been recognized through several accolades, including being awarded as a top graduate innovative talent during his master’s studies. This honor reflects his exceptional contributions to scientific inquiry and innovation.

Publications 📖

Dr. Qu has an impressive publication record, with notable papers such as:

  1. Multiple primary malignancies and gut microbiome

    • Year: 2025

    • Authors: Yinhang Wu, Zhanbo Qu, Zheng Wu, Jing Zhuang, Yingchen Wang, Zefeng Wang, Jian Chu, Quan Qi, Shuwen Han

  2. Fecal occult blood affects intestinal microbial community structure in colorectal cancer

    • Year: 2025

    • Authors: Wu Guodong, Wu Yinhang, Wu Xinyue, Shen Hong, Chu Jian, Qu Zhanbo, Han Shuwen

  3. Aging Gut Microbiome in Healthy and Unhealthy Aging

    • Year: 2024

    • Authors: Zhanbo Qu

  4. Classification of Colorectal Cancer Subtypes Based on Endoplasmic Reticulum Stress

    • Year: 2024

    • Authors: Zhanbo Qu, Jian Chu, Yinhang Wu, Jing Zhuang, Jiang Liu, Shugao Han, Wei Wu, Shuwen Han

  5. Escherichia coli on colorectal cancer: A two‐edged sword

    • Year: 2024 (October)

    • Authors: Chu Jian, Wu Yinhang, Zhuang Jing, Qu Zhanbo, Wang Zefeng, Shuwen Han

  6. Deep learning application in prediction of cancer molecular alterations based on pathological images: a bibliographic analysis via CiteSpace

    • Year: 2024 (October)

    • Authors: Yu Xiaojian, Qu Zhanbo, Chu Jian, Wang Zefeng, Liu Jian, Liu Jin, Pan Yuefen, Han Shuwen

  7. Third-generation PacBio sequencing to explore gut bacteria and gender in colorectal cancer

    • Year: 2024 (July)

    • Authors: Sheng Yu, Jian Chu, Yinhang Wu, Jing Zhuang, Zhanbo Qu, Yifei Song, Xinyue Wu, Shuwen Han

  8. Age and aging process alter the gut microbes

    • Year: 2024 (April 8)

    • Authors: Qu Zhanbo, Zhuang Jing, Han Shugao, Wu Yinhang, Chu Jian, Yu Xiang, Zhao Feimin, Liu Jian, Wu Xinyue, Wu Wei et al.

  9. Transcriptional profile and immune infiltration in colorectal cancer reveal the significance of inducible T‐cell costimulator as a crucial immune checkpoint molecule

    • Year: 2024 (March)

    • Authors: Jian Chu, Yinghang Wu, Zhanbo Qu, Jing Zhuang, Jiang Liu, Shugao Han, Wei Wu, Shuwen Han

  10. Identification of enterotype and its predictive value for patients with colorectal cancer

  • Year: 2024 (February 27)

  • Authors: Li Qingbo, Zhuang Jing, Qu Zhanbo, Chu Jian, Song Yifei, Wu Yinhang, Han Shuwen

Conclusion 🔝

Dr. Qu Zhanbo stands out as a passionate researcher and dedicated doctor whose work bridges clinical practice and scientific exploration. His contributions to microbiology, oncology, and gastroenterology continue to shape the understanding of disease mechanisms and pave the way for future innovations in medical science.